SCHEMBL6397457

SCHEMBL6397457

O=P(O)(O)c1cccc(O)c1CCCc1cccc(O)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.43
CALM1 P0DP23 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
DRD2 P14416 1/20 0.42
DRD1 P21728 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
SLC28A3 Q9HAS3 1/20 0.41
CHRM2 P08172 2/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
HTR2B P41595 1/20 0.39
OPRK1 P41145 1/20 0.39
TYR P14679 1/20 0.38
ENPP2 Q13822 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403912 0.97 MGLL (0.47) MGLLCALM1HDAC6DRD2DRD1
SCHEMBL6395072 0.91 DRD2 (0.45) MGLLCALM1DRD2DRD1TAAR1
SCHEMBL6404256 0.89 SLC28A3 (0.47) MGLLCALM1HDAC6DRD2DRD1
SCHEMBL6398018 0.86 MGLL (0.47) MGLLCALM1HDAC6DRD2DRD1
SCHEMBL6401901 0.85 SLC28A3 (0.50) MGLLCALM1SLC28A3CHRM2CHRM1
SCHEMBL6401970 0.82 ACHE (0.49) MGLLSLC28A3CHRM2CHRM1CHRM3
SCHEMBL6397091 0.80 MGLL (0.41) MGLLCALM1HDAC6DRD2DRD1
SCHEMBL6395816 0.80 MGLL (0.41) MGLLCALM1HDAC6DRD2DRD1
SCHEMBL6397173 0.79 DRD2 (0.45) MGLLCALM1DRD2DRD1TAAR1
SCHEMBL6403060 0.79 ACHE (0.50) MGLLHDAC6DRD2DRD1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MGLL 3457/4885CALM1 2071/4885HDAC6 4653/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MGLL 3439/4885CALM1 2102/4885HDAC6 4532/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MGLL 3457/4885CALM1 2071/4885HDAC6 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.